Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 227

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 227
---
 Warrant Agreement to the description of the terms of the APx Warrants and the SPAC Warrant Agreement set forth in APx’s IPO prospectus, or curing, correcting or supplementing any defective provision contained herein or adding or changing any other provisions with respect to matters or questions arising under the SPAC Warrant Agreement as the parties may deem necessary or desirable and that the parties deem shall not adversely affect the interest of the holders. The SPAC Warrant Agreement, however, requires the approval by the holders of at least a majority of the then -outstandingAPx Warrants to make any change that adversely affects the interests of the registered holders of APx Warrants. Accordingly, we may amend the terms of the APx Warrants in a manner adverse to a holder if holders of at least a majority of the then -outstandingAPx Warrants approve of such amendment. Although our ability to amend the terms of the APx Warrants with the consent of at least a majority of the then -outstandingAPx Warrants is unlimited, examples of such amendments could be amendments to, among other things, increase the exercise price of the APx Warrants, convert the APx Warrants into cash, shorten the exercise period or decrease the number of shares of Company Shares purchasable upon exercise of an APx Warrant. The APx Warrants may have an adverse effect on the market price of the Public Shares and make it more difficult to effectuate the Business Combination. APx issued Public Warrants to purchase 8,625,000 ordinary shares as part of the APx Units offered in the IPO, and, simultaneously with the closing of its initial public offering, APx issued in a private placement Private Placement Warrants to purchase an aggregate of 8,950,000 ordinary shares. In addition, if the Sponsor or an affiliate of the Sponsor or the Initial Shareholders make any working capital loans, such lender may convert those loans into up to an additional 1,500,000 Private Placement Warrants, at the price of $1.00 per Private Placement Warrant. To the extent APx issues ordinary shares to effectuate the Business Combination, the potential for the issuance of a substantial number of additional ordinary shares upon exercise of these APx Warrants could make APx a less attractive acquisition vehicle. Such APx Warrants, when exercised, will increase the number of issued and outstanding ordinary shares and reduce the value of the ordinary shares issued to complete the Business Combination. The holders of Public Warrants,